Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.
Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.
Enter a peptide, product, condition or location. Try generic names, brand names and development codes separately. Results are registry search matches, not automatically verified links to a WPF peptide record.
Search terms are sent to ClinicalTrials.gov and appear in the page URL. Do not enter personal or medical identifying information. Registry records are served with up to a one-hour cache; registry updates themselves can lag real-world changes.
Registry search results
Matching records; showing 4 on this page, newest registry updates first. Search checked 2026-10-07 18:56 UTC. Counts are registry matches, not unique peptides or a worldwide total.
Start: 2021-08-02. Completion: 2022-07-07 (may be estimated). Results are posted in this registry.
Products and interventions (4)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Semaglutide 2.4 mg (drug)
Cagrilintide 2.4 mg (drug)
Placebo (semaglutide) (drug)
Placebo (cagrilintide) (drug)
Where the study takes place — 23 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Uni of Alabama at BirminghamBirmingham, Alabama, United States
Explore the world’s study registries
These links open external registries; their records are not merged into the results above. WHO ICTRP provides a broader search across contributing registries. Search the same generic name, aliases and development codes in relevant regions. One multinational study may appear in more than one registry, so compare registration identifiers before counting it twice.
Start: 2023-04-05. Completion: 2024-12-19 (may be estimated). No results posted in this registry response.
Products and interventions (1)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Cagrilintide (drug) — also listed as: NNC0174-0833
Where the study takes place — 4 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Pharmaceutical Research Associates CZ, s.r.o. Prague, Czechia Site recruitment: Not reported
APEX Research München, Germany Site recruitment: Not reported
Summit Clinical Research s.r.o. Bratislava, Slovakia Site recruitment: Not reported
Summit Clinical Research s.r.o. Malacky, Slovakia Site recruitment: Not reported
Start: 2021-07-07. Completion: 2022-02-16 (may be estimated). No results posted in this registry response.
Products and interventions (3)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Cagrilintide (drug)
semaglutide (drug)
Cagrilintide and semaglutide (drug)
Where the study takes place — 2 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Altasciences Company Inc. Montreal, Quebec, Canada Site recruitment: Not reported
Novo Nordisk Investigational Site Søborg, Denmark Site recruitment: Not reported
Start: 2023-04-12. Completion: 2023-09-18 (may be estimated). No results posted in this registry response.
Products and interventions (4)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Cagrilintide (drug) — also listed as: Cagrilintide A, NNC0174-0833 A
Cagrilintide Placebo (drug) — also listed as: Cagrilintide A, NNC0174-0833 A
Moxifloxacin (drug) — also listed as: Moxifloxacinratiopharm
Moxifloxacin Placebo (drug)
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Parexel International GmbH Berlin, Germany Site recruitment: Not reported
Registry directory checked October 5, 2026 against the WHO registry network. This is a starting point, not complete coverage of every country or continent. Record availability, language and update schedules vary by registry.
